Rise Of The Biosimilar Formulary: CVS Excludes Lantus, Neupogen For 2017
Zarxio and Basaglar will be the beneficiaries of the cost-cutting move, although how much it will help the follow-on products remains unclear.
You may also be interested in...
Johnson & Johnson and Roche launched the big pharma quarterly reporting season. Next up are Novartis, Lilly, Merck, Bayer, GSK, Bristol-Myers Squibb, Amgen and Sanofi. Scrip offers some key points to watch for.
Amgen is the leader in approved bispecific antibodies and oncolytic viruses, but the company's not shy about expanding its oncology pipeline with even more modes of delivering medicines to cancer patients.
Sandoz announces 'complete response' letter for its pegfilgrastim 351(k) filing, suggesting it’s a tough molecule to crack at the agency.